Title and Organization:
J. Joseph Kim, MBA, PhD, is co-founder and former CEO of Inovio, a biotechnology company leading the world in developing immunotherapies—medicines that train the body's immune system to attack a broad array of cancers and challenging infectious diseases, such as COVID-19, influenza, Ebola, and HIV/AIDS. He previously developed vaccines for Merck & Co. Joseph has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. In 2015, Joseph was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region. He serves on the board of the International Vaccine Institute, and The World Economic Forum selected him as a member of its Global Agenda Council and named him a “Technology Pioneer.” The Forum also selected him as one of its Young Global Leaders among 175 top executives chosen from 50 countries. MIT’s Technology Review magazine called him "one of the world’s top innovators." An immunologist by training, Joseph holds an MIT undergraduate degree, a PhD in biochemical engineering from the University of Pennsylvania, and an MBA from Wharton. Joseph is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.